Navigation Links
Perrigo Announces Final FDA Approval of Dexcel's OTC Omeprazole; Raises Full Year Earnings Guidance
Date:12/10/2007

ALLEGAN, Mich., Dec. 10 /PRNewswire-FirstCall/ -- The Perrigo Company (Nasdaq: PRGO; TASE) announced today that the U.S. Food & Drug Administration (FDA) has granted final approval to Dexcel Pharma Technologies, Ltd. for 20 mg Omeprazole delayed-release tablets. As the exclusive marketer and distributor of this product for the store brand over-the-counter (OTC) market in the United States, Perrigo expects to begin shipping its product during the first quarter of calendar year 2008, with full year annual sales to be in the range of $150 - $200 million.

Perrigo's Chairman and CEO Joseph C. Papa stated, "The approval from the FDA is the final regulatory step for this exclusive product launch, which we expect to be the largest product in Perrigo's 120 year history. While we are excited about the opportunity, we will obviously continue investing in research and development to add more new products to our product offering. The launch of Omeprazole is another example of Perrigo's dedication to make quality healthcare more affordable."

Based on pre-launch estimates, Perrigo's Omeprazole product is expected to contribute between $0.20 and $0.25 earnings per share in fiscal year 2008. As a result of the Omeprazole launch, full year earnings for fiscal year 2008 are expected to be in the range of $1.32 to $1.47 per share.

Prilosec OTC(R) is indicated for the treatment of frequent heartburn and had estimated current annual sales of approximately $750 million in all outlets.

Headquartered in Or Akiva, Israel, Dexcel Pharma Technologies, Ltd. is a privately-held, international specialty pharmaceutical company which focuses on the development, manufacture and marketing of innovative prescription, generic prescription, and OTC
'/>"/>

SOURCE The Perrigo Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Philadelphia, Pa. (PRWEB) September 22, 2014 ... develops rapid diagnostics for the food and beverage ... assay will be distributed under a non-exclusive agreement ... products and services. , Enartis, an Esseco Group ... BRETT to winemakers in California and other global ...
(Date:9/22/2014)... The US markets on Friday, September 19, ... Jones Industrial Average finished at 17,279.74, up 0.08% and ... S&P 500 finished the session 0.05% lower at 2,010.40. ... finished on a positive note. The S&P 500 Health ... 0.10%, with the index gaining 6.95% in the previous ...
(Date:9/21/2014)... time, scientists have discovered how to produce ultra-thin "diamond ... greater than that of today,s strongest nanotubes and polymers. ... led by John V. Badding, a professor of chemistry ... 21 September 2014 issue of the journal Nature ... our discovery is intriguing because the threads we formed ...
(Date:9/19/2014)... -- InterMune, Inc. (Nasdaq: ITMN ) today announced ... settle the litigation in the Delaware Court of Chancery ... as of August 22, 2014, among Roche Holdings, Inc., ... of the Memorandum of Understanding, the Company agreed to ... exhibit reflecting the amendment to the Company,s Schedule 14D-9 ...
Breaking Biology Technology:Invisible Sentinel's Test for Wine-Spoilage Microbe to be Distributed by Enartis in Multiple Markets Globally 2Invisible Sentinel's Test for Wine-Spoilage Microbe to be Distributed by Enartis in Multiple Markets Globally 3Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 2Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 3Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 4Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 5Smallest possible diamonds form ultra-thin nanothreads 2Smallest possible diamonds form ultra-thin nanothreads 3Smallest possible diamonds form ultra-thin nanothreads 4InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 2InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 3InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 4InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 5InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 6InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 7InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 8InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 9InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 10InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 11InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 12InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 13InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 14InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 15InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 16InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 17InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 18InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 19
... 2011 Pharmaceutical organizations rely heavily on internal ... Faced with a constantly evolving communication environment, companies ... with the most appropriate tactic. It ... is the most effective approach for the many ...
... discovery of a new class of dual-acting antimalarial compounds - ... Science online, at the Science Express website ... and blood infections, attacking the Plasmodium parasite at both stages ... how scientists developed a novel assay to determine liver stage ...
... Today BioSpace , the leading life sciences employment ... Campaign , marking the 7th edition. ... highlights leading organizations across the northwestern United States and ... electronic and printed campaign map that is ...
Cached Biology Technology:Internal and External Communications Excellence for the Pharmaceutical Industry: Increasing Organizational Effectiveness 2Dual-acting class of antimalarial compounds discovered with potential to prevent and treat malaria 2Dual-acting class of antimalarial compounds discovered with potential to prevent and treat malaria 3BioSpace Spotlights Northwest's Life Science Community 2
(Date:9/21/2014)... In recent years, new strains of bacteria have emerged ... these superbugs, including drug-resistant forms of tuberculosis and staphylococcus, ... at least 23,000. Despite the urgent need for new ... antibiotics in the past decade. , MIT engineers have ... Using a gene-editing system that can disable any target ...
(Date:9/21/2014)... barnacles secrete very sticky proteins that help them cling ... these natural adhesives, a team of MIT engineers has ... ships or help heal wounds and surgical incisions. , ... engineered bacteria to produce a hybrid material that incorporates ... protein found in biofilms slimy layers formed by ...
(Date:9/19/2014)... Jimmy Durante of dinosaurs a newly discovered ... new dinosaur, named Rhinorex condrupus by ... Young University, lived in what is now Utah ... Cretaceous period. , Rhinorex, which translates roughly into ... relative of other Cretaceous hadrosaurs like Parasaurolophus and ...
Breaking Biology News(10 mins):Battling superbugs 2Battling superbugs 3Battling superbugs 4Engineered proteins stick like glue -- even in water 2Engineered proteins stick like glue -- even in water 3New hadrosaur noses into spotlight 2
... The U.S. Department of Energys Office of Science ... publication, Facilities for the Future of Science: A Twenty-Year ... in deploying the scientific facilities and instruments that the ... the frontiers of science and support the Departments missions. ...
... -- Growing recognition of the importance of health as ... has prompted the Proceedings of the National Academy of ... Health to its existing section on Sustainable Development. The ... editorial by Barry R. Bloom, Dean of the Harvard ...
... has published recent findings that reveal some of the factors underlying ... The paper, Stem Cell Aging is Controlled both Intrinsically and ... issue of Cell Stem Cell. Lei Pan, Predoctoral Researcher, and Ting ... respectively. It is widely ...
Cached Biology News:DOE publishes update of plan: 'Facilities for the Future of Science: A 20-Year Outlook' 2DOE publishes update of plan: 'Facilities for the Future of Science: A 20-Year Outlook' 3DOE publishes update of plan: 'Facilities for the Future of Science: A 20-Year Outlook' 4DOE publishes update of plan: 'Facilities for the Future of Science: A 20-Year Outlook' 5Data on life expectancy show many countries clustered in high mortality traps 2Data on life expectancy show many countries clustered in high mortality traps 3Stowers Institute's Xie Lab demonstrates dual intrinsic and extrinsic control of stem cell aging 2